Current adeno-associated virus (AAV) gene therapies are limited by a lack of tissue-specificity, leading to toxic off-target impacts and increased therapeutic costs. More target-specific AAV vectors can offer safer and less expensive therapies. Antibody-like p... ...

请注册登录后继续浏览